Liver Cancer

Papers
(The median citation count of Liver Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Imaging Diagnosis of Various Hepatocellular Carcinoma Subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence442
Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis148
Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents103
Physical Activity Improves Overall Survival in Patients with Hepatocellular Carcinoma81
Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review71
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Exp59
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma55
Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma50
Front & Back Matter49
Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma44
Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis44
Treatment Decision Making in Unresectable HCC: Importance to Understand the Different Response Patterns Between IO Plus Anti-VEGF and IO Plus IO Regimens in Hepatocellular Carcinoma41
Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study40
Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis40
M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma37
Lenvatinib Versus Sorafenib in First-Line Treatment of Older Patients With Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial33
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study32
Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study30
Reply to the Comment on the Article “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma”30
Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma30
The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association with Tumor Microenvironment and Ferroptosis27
Society News27
Comparative Study of Laparoscopic Hepatectomy, Open Hepatectomy, and Percutaneous Radiofrequency Ablation for Small Hepatocellular Carcinoma: An Ancillary Study of the SURF Trial27
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis26
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification26
Alcohol plays a detrimental role in the prognosis of hepatocellular carcinoma related to steatotic liver disease26
Erratum25
Was Concurrent Antibiotic Use during Immunotherapy Associated with Higher Mortality for Patients with Advanced Hepatocellular Carcinoma?25
Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma24
Plasma Adiponectin Levels in Relation to Chronic Hepatitis B Infection Progression to Liver Cancer Milestones: A Prospective Study23
Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicente22
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study22
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma21
The Evolving Role of Imaging in Hepatocellular Carcinoma: From Pathomolecular Profiling to Prognostic Decision-Making21
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab21
Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 20
Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis20
Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma20
Definition of Conversion Therapy and Neoadjuvant Therapy for Hepatocellular Carcinoma: A Consensus Guideline from the Japan Liver Cancer Association20
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis19
All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy19
Erratum18
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study18
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis18
Assessment of Survival Benefits Derived from Surgical Resection Subsequent to the Attainment of Complete Response upon Triple Therapy in Hepatocellular Carcinoma: A Multicenter Study18
Dissecting the Transcriptomic Profile of CD163 + Macrophages in Hepatocellular Carcinoma with VETC + 18
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study17
Erratum17
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma17
Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma17
Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis17
Real-World Evidence from a Nationwide Prospective Study of the Efficacy/Safety of Systemic Therapy for Unresectable Hepatocellular Carcinoma: First 1,000 Patients of the PRISM Study16
Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity16
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma16
Acknowledgement to Reviewers16
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study16
MRI Using Gadoxetic Acid in the Work-Up of Liver Nodules Not Conclusively Benign in Budd-Chiari Syndrome: A Prospective Long-Term Follow-Up16
Liver Stiffness Measured by Vibration-Controlled Transient Elastography Predicts Hepatic Decompensation in Patients with Hepatocellular Carcinoma Receiving Systemic Treatments16
Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence15
Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy15
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy15
Machine Learning Models for Disease-Free Survival Analysis after Liver Resection for Hepatocellular Carcinoma: A Multicentric French Collaborative Study15
Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma14
Society News14
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular14
Role of Particle Therapy for Intrahepatic Cholangiocarcinoma; Meta-Analysis for Comparison with Standard Therapy: TRP-Intrahepatic Cholangiocarcinoma 202514
An updated systematic review and meta-analysis of modern radiotherapy techniques for hepatocellular carcinoma13
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety13
Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma13
Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma12
Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma12
Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations12
Imaging-Based Liver Transplant Eligibility in Hepatocellular Carcinoma: Analysis of 1,094 Patients Using Liver Imaging Reporting and Data System and Asia-Pacific Guideline-Based Criteria12
Erratum12
Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score12
Pathological Complete Response after Systemic Therapy and Curative Resection in Initially Unresectable Hepatocellular Carcinoma: Feasibility of a Tumor-Free with Drug-Free Strategy12
Front & Back Matter11
Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”11
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial11
Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression10
Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan10
Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis10
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment10
Comment on the Article “Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma”10
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study10
Reply to the Letter regarding “Combination Assay of Methylated HOXA1 with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma”10
Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma10
Society News10
Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis9
Society News9
Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004–20199
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis9
No More Detours: Hepatopulmonary Shunt Reduction in a Patient with Hepatocellular Carcinoma after Treatment with Bevacizumab9
Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-9
Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma9
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study9
A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial8
HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct Features8
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases8
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis8
Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population8
Patient and Physician Preferences for Add-On Systemic Therapy to Transarterial Chemoembolization for Hepatocellular Carcinoma in Japan: A Discrete Choice Experiment8
Reply to “Methodological Concerns in ‘Prognostic Usefulness of Clinical Complete Response after PD1 InhibitorBased Combination Therapy for Unresectable Hepatocellular Carcinoma’ ”8
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)8
Acknowledgement to Reviewers7
The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors7
Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Hepatocellular Carcinoma ≤5 cm: Biological Characteristics and Patient Outcomes7
Oncological Outcomes and Treatment Strategies for Borderline Resectable Hepatocellular Carcinoma Based on the Oncological Resectability Classification7
Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria7
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial7
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD6
Erratum6
Proton Beam Therapy for Untreated Hepatocellular Carcinoma Unsuitable for Transcatheter Arterial Chemoembolization6
Preoperative Prediction of Microvascular Invasion with Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Patients with Single Hepatocellular Carcinoma: The Implication of Surgical Decision on the 6
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management6
The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer6
PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer6
Stable Disease without Tumor Shrink Cannot Benefit from Surgery following Immune-Based Therapy in Potentially Resectable Hepatocellular Carcinoma6
Antibiotics Associated with Lower Survival in Hepatocellular Cancer Patients Receiving Immune Checkpoint Inhibitors Independent of Tumor Status6
Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Be6
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study6
Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma5
A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma5
Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab5
Erratum5
Vessels That Encapsulate Tumor Cluster+ Unresectable Hepatocellular Carcinomas Benefit of Antiangiogenic Therapy5
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)5
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 1165
Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease5
Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis5
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery5
Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography: A Potential Imaging Biomarker for Predicting Response to Combination Immunotherapy in Hepatocellular Carcinoma5
Transarterial Chemoembolization plus Sorafenib versus Sorafenib Alone in Advanced Hepatocellular Carcinoma (SELECT): A Multicenter, Phase 3, Randomized, Controlled Trial5
The Risk of Decompensation in Steatotic Liver Disease Related Hepatocellular Carcinoma: A Comparison with Viral-controlled Cases5
Comparison of Gadoxetic Acid-enhanced Liver MRI and Contrast-enhanced CT for the Noninvasive Diagnosis of Hepatocellular Carcinoma4
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis 4
Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy4
Patterns and Prognostic Stratification of Recurrence after Thermal Ablation in Patients with Hepatocellular Carcinoma4
Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis4
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries4
Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study4
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular Carcinoma4
Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma4
Hepatic Resection versus Stereotactic Body Radiation Therapy as Initial Local Treatment for BCLC Stage 0 Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis4
Lenvatinib as Second-Line Regimen after Atezolizumab plus Bevacizumab Combination Therapy4
Exposure to poly- and perfluoroalkyl substances and risk of hepatocellular carcinoma in male patients with cirrhosis related to HCV infection4
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression3
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carci3
Front & Back Matter3
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma3
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials3
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma3
Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study3
Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location3
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma3
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study3
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular Carcinoma3
Curative Treatment after Immunotherapy Leads to Excellent Outcomes in Patients with Hepatocellular Carcinoma3
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis3
Primary Analysis of a Phase II Study of Atezolizumab plus Bevacizumab for TACE-Unsuitable Patients with Tumor Burden beyond Up-To-Seven Criteria in Intermediate-Stage Hepatocellular Carcinoma: REPLACE3
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave1503
Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review3
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B3
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)3
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma3
Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis3
0.20822501182556